428 related articles for article (PubMed ID: 17530260)
1. Epidemiology of urinary bladder cancer: from tumor development to patient's death.
Murta-Nascimento C; Schmitz-Dräger BJ; Zeegers MP; Steineck G; Kogevinas M; Real FX; Malats N
World J Urol; 2007 Jun; 25(3):285-95. PubMed ID: 17530260
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for bladder cancer.
Janković S; Radosavljević V
Tumori; 2007; 93(1):4-12. PubMed ID: 17455864
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
McGrath M; Michaud D; De Vivo I
BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and risk factors of urothelial bladder cancer.
Burger M; Catto JW; Dalbagni G; Grossman HB; Herr H; Karakiewicz P; Kassouf W; Kiemeney LA; La Vecchia C; Shariat S; Lotan Y
Eur Urol; 2013 Feb; 63(2):234-41. PubMed ID: 22877502
[TBL] [Abstract][Full Text] [Related]
5. Environmental non-occupational risk factors associated with bladder cancer.
Ferrís J; Berbel O; Alonso-López J; Garcia J; Ortega JA
Actas Urol Esp; 2013 Oct; 37(9):579-86. PubMed ID: 23618510
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer risk from occupational and environmental exposures.
Kiriluk KJ; Prasad SM; Patel AR; Steinberg GD; Smith ND
Urol Oncol; 2012; 30(2):199-211. PubMed ID: 22385990
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of urothelial carcinoma.
Miyazaki J; Nishiyama H
Int J Urol; 2017 Oct; 24(10):730-734. PubMed ID: 28543959
[TBL] [Abstract][Full Text] [Related]
9. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
Hung RJ; Boffetta P; Brennan P; Malaveille C; Hautefeuille A; Donato F; Gelatti U; Spaliviero M; Placidi D; Carta A; Scotto di Carlo A; Porru S
Int J Cancer; 2004 Jul; 110(4):598-604. PubMed ID: 15122594
[TBL] [Abstract][Full Text] [Related]
10. Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.
Carta A; Pavanello S; Mastrangelo G; Fedeli U; Arici C; Porru S
Int J Environ Res Public Health; 2018 Jul; 15(8):. PubMed ID: 30042310
[No Abstract] [Full Text] [Related]
11. Epidemiology and etiology of bladder cancer.
Cohen SM; Johansson SL
Urol Clin North Am; 1992 Aug; 19(3):421-8. PubMed ID: 1636227
[TBL] [Abstract][Full Text] [Related]
12. Bladder Cancer Working Group report.
Kakehi Y; Hirao Y; Kim WJ; Ozono S; Masumori N; Miyanaga N; Nasu Y; Yokomizo A
Jpn J Clin Oncol; 2010 Sep; 40 Suppl 1():i57-64. PubMed ID: 20870921
[TBL] [Abstract][Full Text] [Related]
13. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
14. Tobacco use and occupational exposure to carcinogens, but not N-acetyltransferase 2 genotypes are major risk factors for bladder cancer in the Japanese.
Kontani K; Kawakami M; Nakajima T; Katsuyama T
Urol Res; 2001 Jun; 29(3):199-204. PubMed ID: 11482447
[TBL] [Abstract][Full Text] [Related]
15. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
Antoni S; Ferlay J; Soerjomataram I; Znaor A; Jemal A; Bray F
Eur Urol; 2017 Jan; 71(1):96-108. PubMed ID: 27370177
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
17. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk.
Zhao H; Lin J; Grossman HB; Hernandez LM; Dinney CP; Wu X
Int J Cancer; 2007 May; 120(10):2208-13. PubMed ID: 17290402
[TBL] [Abstract][Full Text] [Related]
18. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
19. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology of and risk factors for bladder cancer and for urothelial tumors].
Guillaume L; Guy L
Rev Prat; 2014 Dec; 64(10):1372-4, 1378-80. PubMed ID: 25668830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
